the talktank
LSE SU Entrepreneurs
Podcast
Episodes
Listen, download, subscribe
Robert Barrow - The Psychedelic Transformation
The Bits & Bytes Series - Robert Barrow Hosted by Sia Sha Robert Barrow is the CEO of MindMed, a psychedelic biotech company founded in 2019. MindMed was the first psychedelic company that was listed on the Nasdaq and is currently in clinical trials - for example, for exploring the efficacy of LSD on generalised anxiety disorder. 🧠📚 The company has a market cap of roughly 700m and has received investment from individuals such as Kevin O’Leary. 🏋️‍♀️ Rethink your brain health: https://mindmed.co/ Timestamps: 1:35 - What are psychedelics? 2:45 - Why are psychedelics controversial? Is the controversy based on valid concerns? 7:25 - Has depression, anxiety, and disconnection been on the rise in recent years? Why is therapy not enough? 17:12 - Rob talks about his journey through MindMed, from a consultant to CEO, and the potential he saw in the company. 31:39 - Rob discuss development of psychedelics and how they plan to take it to market. 32:05 - Are there any adverse effects of the usage of psychedelics? How does MindMed test for them? 45:19 - How do psychedelics work on anxiety disorder? 1:00:00 - Rob discusses the end goal and vision of MindMed, and who he would like as colleagues in the company. 01:01:47 - Why did MindMed go public? 1:10:07 - Rob discuss planning for distribution channels
the talktank RSS Feed
